Open Access

REVIEW

DHANYA K. NAMBIAR¹, DEEPALI MISHRA², RANA P. SINGH^2,3,*
Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310 - 25 June 2023
Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More >

Graphic Abstract

View

2102

Download

989

Open Access

REVIEW

LAURA MARRONE¹, MASSIMO D’AGOSTINO¹, CAROLINA GIORDANO², VALERIA DI GIACOMO¹, SIMONA URZINI¹, CHIARA MALASOMMA¹, MARIA PAOLA GAMMELLA¹, MARTINA TUFANO¹, SIMONA ROMANO^1,*, MARIA FIAMMETTA ROMANO^1,*
Oncology Research, Vol.31, No.4, pp. 423-436, 2023, DOI:10.32604/or.2023.028392 - 25 June 2023
Abstract Scaffold proteins are crucial regulators of signaling networks, and their abnormal expression may favor the development of tumors. Among the scaffold proteins, immunophilin covers a unique role as ‘protein-philin’ (Greek ‘philin’ = friend) that interacts with proteins to guide their proper assembly. The growing list of human syndromes associated with the immunophilin defect underscores the biological relevance of these proteins that are largely opportunistically exploited by cancer cells to support and enable the tumor’s intrinsic properties. Among the members of the immunophilin family, the FKBP5 gene was the only one identified to have a splicing variant. More >

Graphic Abstract

View

1106

Download

606

Open Access

REVIEW

HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*
Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924 - 25 June 2023
Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen More >

Graphic Abstract

View

1788

Download

635

Like

1

Open Access

REVIEW

LEI ZHANG^*, YUAN ZHANG, HUIJUAN GAO, XIN LI, PEIFENG LI^*
Oncology Research, Vol.31, No.4, pp. 449-462, 2023, DOI:10.32604/or.2023.029062 - 25 June 2023
Abstract Glioblastoma (GBM) is the most malignant form of glioma and is difficult to diagnose, leading to high mortality rates. Circular RNAs (circRNAs) are noncoding RNAs with a covalently closed loop structure. CircRNAs are involved in various pathological processes and have been revealed to be important regulators of GBM pathogenesis. CircRNAs exert their biological effects by 4 different mechanisms: serving as sponges of microRNAs (miRNAs), serving as sponges of RNA binding proteins (RBPs), modulating parental gene transcription, and encoding functional proteins. Among the 4 mechanisms, sponging miRNAs is predominant. Their good stability, broad distribution and high More >

Graphic Abstract

View

1089

Download

574

Open Access

ARTICLE

LI TIAN^1,#, YONGYI HUANG^1,#, BAOZHEN ZHANG^2,#, YI SONG^1,#, LIN YANG³, QIANQIAN CHEN¹, ZHENG WANG³, YILING WANG¹, QIHAN HE¹, WENHAN YANG¹, SHUYONG YU⁴, TIANYU LU⁵, ZICHEN LIU¹, KAIPING GAO^1,*, XIUJUN FAN^2,*, JIAN SONG^4,*, RIHONG ZHAI^1,*
Oncology Research, Vol.31, No.4, pp. 463-479, 2023, DOI:10.32604/or.2023.028791 - 25 June 2023
Abstract Accumulating evidence has indicated that long non-coding RNAs (lncRNAs) play critical roles in the development and progression of cancers, including esophageal squamous cell carcinoma (ESCC). However, the mechanisms of lncRNAs in ESCC are still incompletely understood and therapeutic attempts for in vivo targeting cancer-associated lncRNA remain a challenge. By RNA-sequencing analysis, we identified that LLNLR-299G3.1 was a novel ESCC-associated lncRNA. LLNLR-299G3.1 was up-regulated in ESCC tissues and cells and promoted ESCC cell proliferation and invasion. Silencing of LLNLR-299G3.1 with ASO (antisense oligonucleotide) resulted in opposite effects. Mechanistically, LLNLR-299G3.1 bound to cancer-associated RNA binding proteins and regulated the expression… More >

View

1150

Download

779

Open Access

ARTICLE

FAYU SHAN¹, LANLAN LIANG¹, CHONG FENG¹, HONGBAO XU¹, ZIROU WANG¹, WEILI LIU¹, LINGLING PU¹, ZHAOLI CHEN¹, GANG CHEN^2,*, XINXING WANG^1,*
Oncology Research, Vol.31, No.4, pp. 481-493, 2023, DOI:10.32604/or.2023.029064 - 25 June 2023
Abstract Background: Oral squamous cell carcinoma (OSCC) is a common malignant tumor. Recently, Laminin Gamma 2 (LAMC2) has been shown to be abnormally expressed in OSCC; however, how LAMC2 signaling contributes to the occurrence and development of OSCC and the role of autophagy in OSCC has not been fully explored. This study aimed to analyze the role and mechanism of LAMC2 signaling in OSCC and the involvement of autophagy in OSCC. Methods: To explore the mechanism by which LAMC2 is highly expressed in OSCC, we used small interfering RNA (siRNA) to knock down LAMC2 to further… More >

View

1463

Download

704

Open Access

ARTICLE

CHIWEN BU^1,2, LIGANG ZHAO¹, LISHAN WANG¹, ZEQIAN YU¹, JIAHUA ZHOU^1,*
Oncology Research, Vol.31, No.4, pp. 495-503, 2023, DOI:10.32604/or.2023.029309 - 25 June 2023
Abstract Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the More >

Graphic Abstract

View

1102

Download

528

Open Access

ARTICLE

XIN LI^1,2,#, WENKAI JIANG^3,#, WANCHENG LI^3,#, SHI DONG³, YAN DU³, HUI ZHANG^1,*, WENCE ZHOU^1,3,*
Oncology Research, Vol.31, No.4, pp. 505-514, 2023, DOI:10.32604/or.2023.026959 - 25 June 2023
Abstract Background: The dilemma of pancreatic cancer treatment has become a global challenge. For this reason, effective, feasible, and new medical methods are currently much-needed. Betulinic acid (BA) has been valued as a potential therapy for pancreatic cancer. However, the mechanism by which BA exerts an inhibitory effect on the development of pancreatic cancer remains elusive. Methods: A rat model and two cell models of pancreatic cancer were established, and the effect of BA on pancreatic cancer was verified in vivo and in vitro by using MTT, Transwell, flow cytometry, RT-PCR, Elisa and immunohistochemistry. At the same time,… More >

Graphic Abstract

View

1116

Download

574

Open Access

ARTICLE

MIN WANG^1,#, HAILIANG ZHAO^1,2,#, WEIWEI CHEN^3,#, CAIQUN BIE^4,#, JINYING YANG¹, WENRUI CAI¹, CHUTIAN WU¹, YANFANG CHEN¹, SHUFEN FENG¹, YING SHI¹, YUTING LI¹, HUIJUN TANG⁴, LIXIAN ZHONG¹, LILIANGZI GUO¹, SISI CHEN¹, LINJING LONG⁵, SHAOHUI TANG^1,*
Oncology Research, Vol.31, No.4, pp. 515-541, 2023, DOI:10.32604/or.2023.029101 - 25 June 2023
Abstract The dysregulation of exosomal microRNAs (miRNAs) plays a crucial role in the development and progression of cancer. This study investigated the role of a newly identified serum exosomal miRNA miR-4256 in gastric cancer (GC) and the underlying mechanisms. The differentially expressed miRNAs were firstly identified in serum exosomes of GC patients and healthy individuals using next-generation sequencing and bioinformatics. Next, the expression of serum exosomal miR-4256 was analyzed in GC cells and GC tissues, and the role of miR-4256 in GC was investigated by in vitro and in vivo experiments. Then, the effect of miR-4256 on its… More >

Graphic Abstract

View

1042

Download

601

Open Access

ARTICLE

WUYAO LIU, CHANGBAO QU, XIAOLU WANG^*
Oncology Research, Vol.31, No.4, pp. 543-567, 2023, DOI:10.32604/or.2023.029563 - 25 June 2023
（This article belongs to the Special Issue: Application of Multi-omics Analysis in Cancer Immunotherapy)
Abstract The high immune infiltration and heterogeneity of the microenvironment in clear cell renal cell carcinoma (ccRCC) result in the variability of prognosis and clinical response. While PANoptosis has strong immunogenicity and is worthy of further study. In this study, data from The Cancer Genome Atlas database was used to obtain immune-related PANoptosis lncRNAs with prognostic value. Subsequently, the role of these lncRNAs in cancer immunity, progression and the therapeutic response was analyzed, and a new prediction model was constructed. Additionally, we further explored the biological value of PANoptosis-related lncRNAs using single-cell data from the Gene… More >

View

1552

Download

749

Open Access

ARTICLE

XINRUI SHI¹, XIA GAO¹, WENCONG LIU², XUEJIAO TANG¹, JIAYI LIU¹, DONGCHEN PAN¹, XUEQING DUAN¹, YUQING JIN¹, WEIYAN REN¹, LEI YANG^1,*, WENXUAN LIU^1,*
Oncology Research, Vol.31, No.4, pp. 569-590, 2023, DOI:10.32604/or.2023.028964 - 25 June 2023
（This article belongs to the Special Issue: Role of Reactive Oxygen Species and DNA Damage in Tumor Immunological Responses)
Abstract Hepatocellular carcinoma (HCC) is the most common fatal cancer worldwide, patients with HCC have a high mortality rate and poor prognosis. PANoptosis is a novel discovery of programmed cell death associated with cancer development. However, the role of PANoptosis in HCC remains obscure. In this study, we enrolled 274 PANoptosisrelated genes (PANRGs) and screened 8 genes to set up a prognostic model. A previous scoring system calculated PANscore was utilized to quantify the individual risk level of each HCC patient, and the reliability of the prognostic model has been validated in an external cohort. Nomogram More >

View

2607

Download

801

Open Access

ARTICLE

TIANMING SHI^1,2,#, RONGRONG YAN^1,2,#, MI HAN^1,2,*
Oncology Research, Vol.31, No.4, pp. 591-604, 2023, DOI:10.32604/or.2023.029282 - 25 June 2023
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Ovarian cancer (OV) is highly heterogeneous tumor with a very poor prognosis. Studies increasingly show that T cell exhaustion is prognostically relevant in OV. The aim of this study was to dissect the heterogeneity of T cell subclusters in OV through single cell transcriptomic analysis. The single RNA-sequencing (scRNA-seq) data of five OV patients were analyzed, and six major cell clusters were identified after threshold screening. Further clustering of T cell-associated clusters revealed four subtypes. Pathways related to oxidative phosphorylation, G2M checkpoint, JAK-STAT and MAPK signaling were significantly activated, while the p53 pathway was inhibited… More >

Graphic Abstract

View

1369

Download

674

Open Access

ARTICLE

SHA ZHU^#, NANWEI XU^#, JIAYU LIANG, FENGNIAN ZHAO, ZILIN WANG, YUCHAO NI, JINDONG DAI, JINGE ZHAO, XINGMING ZHANG, JUNRU CHEN, GUANGXI SUN, PENGFEI SHEN^*, HAO ZENG^*
Oncology Research, Vol.31, No.4, pp. 605-614, 2023, DOI:10.32604/or.2023.028321 - 25 June 2023
Abstract Background: KMT2 (lysine methyltransferase) family enzymes are epigenetic regulators that activate gene transcription. KMT2C is mainly involved in enhancer-associated H3K4me1, and is also one of the top mutated genes in cancer (6.6% in pan-cancer). Currently, the clinical significance of KMT2C mutations in prostate cancer is understudied. Methods: We included 221 prostate cancer patients diagnosed between 2014 and 2021 in West China Hospital of Sichuan University with cell-free DNA-based liquid biopsy test results in this study. We investigated the association between KMT2C mutations, other mutations, and pathways. Furthermore, we evaluated the prognostic value of KMT2C mutations, measured by… More >

View

1159

Download

601

Open Access

ARTICLE

JUNYU HE^1,2,3, FENG ZENG^1,2,3, XI JIN^1,2,3, LIN LIANG^1,2,3, MENGXIANG GAO^1,2,3, WENTAO LI^1,2,3, GUIYUAN LI^1,2,3, YANHONG ZHOU^1,2,3,*
Oncology Research, Vol.31, No.4, pp. 615-630, 2023, DOI:10.32604/or.2023.029698 - 25 June 2023
Abstract Fos-related antigen 1 (Fra-1) is a nuclear transcription factor that regulates cell growth, differentiation, and apoptosis. It is involved in the proliferation, invasion, apoptosis and epithelial mesenchymal transformation of malignant tumor cells. Fra-1 is highly expressed in gastric cancer (GC), affects the cycle distribution and apoptosis of GC cells, and participates in GC occurrence and development. However, the detailed mechanism of Fra-1 in GC is unclear, such as the identification of Fra-1-interacting proteins and their role in GC pathogenesis. In this study, we identified tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta (YWHAH) as a Fra-1-interacting protein… More >

View

1185

Download

863